Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 9029 results

  1. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date:  05 August 2026

    Technology appraisal guidance
    In development

  2. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 19 June 2026.

    Technology appraisal guidance
    In consultation

  3. Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 16 June 2026.

    Technology appraisal guidance
    In consultation

  4. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 8 June 2026.

    Technology appraisal guidance
    In consultation

  5. Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]

    In development Reference number: GID-TA11858 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    In development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    In development Reference number: GID-TA11509 Expected publication date:  24 February 2027

    Technology appraisal guidance
    In development

  8. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTE10072 Expected publication date:  11 February 2027

    In development

  9. Oveporexton for treating type 1 narcolepsy [ID6622]

    In development Reference number: GID-TA11820 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Artificial intelligence (AI) technologies to help detect prostate cancer on MRI

    In development Reference number: GID-HTE10089 Expected publication date:  12 November 2026

    In development

  11. Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma

    In development Reference number: GID-HTG10175 Expected publication date: TBC

    HealthTech guidance
    In development

  12. Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation

    In development Reference number: GID-HTE10066 Expected publication date:  20 August 2026

    In development

  13. Digital technologies to aid the scoring and interpretation of diagnostic sleep studies for obstructive sleep apnoea and rare sleep disorders

    In development Reference number: GID-HTG10174 Expected publication date: TBC

    HealthTech guidance
    In development

  14. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development Reference number: GID-TA10905 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Decitabine–cedazuridine with venetoclax for untreated acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    In development Reference number: GID-TA11765 Expected publication date:  24 March 2027

    Technology appraisal guidance
    In development